Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ENTXBullishCorporate Developmentsnews

High materiality9/10

Entera Bio secures record $275M PIPE to fund EB613 Phase 3.

Jul 29, 2026, 3:03 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Oversubscribed PIPE and extended runway reduce near-term financial risk and support key Phase 3 program, potentially lifting valuation, though dilution risk remains.

AI summary

What happened, with direct paths to the underlying reporting

Entera Bio announced an oversubscribed $275 million PIPE financing, extending its cash runway into 2030 and fully funding EB613 Phase 3. EB613 is the first oral PTH (1-34) tablet for osteoporosis. The deal, the largest Israeli biotech PIPE on record, signals strong investor interest but introduces dilution risk alongside potential upside from imminent Phase 3 milestones.

Entera Bio raises $275M via oversubscribed private placement; extends cash runway to 2030.
EB613 is first oral PTH (1-34) tablet; Phase 3 funding supported.
Largest Israeli biotech PIPE on record; ninth largest Israeli PIPE.
Deal underscores investor demand; Greenberg Traurig led the transaction.
Cash runway extension could de-risk EB613 milestones while diluting shareholders.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Entera Bio secures record $275M PIPE to fund EB613 Phase 3.

Entera Bio secures financing to extend runway and advance EB613 toward FDA

Entera Bio Posts Losses, Suffering Significant Share Price Drop